Clinical trials: Acute Moderate-to-severe Pain
COVID-19
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 in hospitalized patients with moderate to severe Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT05445934
- Testing
- FB2001
- Where
- 2 sites in China
- Volunteers
- 1,188 people
- Sponsor
- Frontier Biotechnologies Inc.
ARDS (Acute Respiratory Distress Syndrome)
Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)
This is a Phase I/II, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of GKL-006RTU injection in participants with moderate to severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT07706855
- Testing
- GKL-006RTU injection
- Volunteers
- 52 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Pneumonia
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult…
- Trial name
- NCT07615010
- Testing
- agenT-797, Standard of Care (SOC)
- Where
- 4 sites in United States, Ukraine
- Volunteers
- 90 people
- Sponsor
- MiNK Therapeutics
Acute Pain
Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea
The primary objective is to evaluate the analgesic efficacy of PBK_L1704 compared with placebo in patients with moderate to severe acute pain after bunionectomy.
- Trial name
- NCT05509868
- Testing
- PBK_L1704 0.35mg, PBK_L1704 0.5mg
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Pharmbio Korea Co., Ltd.
Coronavirus Infections, SARS-CoV 2
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents.
- Conditions
- Coronavirus Infections, SARS-CoV 2, SARS (Severe Acute Respiratory Syndrome), Pulmonary Disease
- Trial name
- NCT04361461
- Testing
- Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Postoperative Pain
A Study to Evaluate the Safety and Tolerability of Fentanyl Iontophoretic Transdermal System (Fentanyl-ITS) in the Management of Post-Surgery Pain
The purpose of this study is to evaluate the safety and tolerability of the fentanyl iontophoretic transdermal (through the skin) system (fentanyl-ITS) in daily clinical practice for management of acute (a quick and severe form…
- Trial name
- NCT01804673
- Testing
- Fentanyl-ITS
- Where
- 22 sites in Germany
- Volunteers
- 174 people
- Sponsor
- Janssen-Cilag G.m.b.H
Pain, Acute
Efficacy and Safety of Penthrox® Combined With a Standard Analgesia (SoC) in Adult Patients Admitted to the Emergency Department With Moderate to Severe Pain Associated With Trauma
A phase 4 randomised, double-blind study to assess the efficacy and safety of Penthrox® used from the outset in multimodal analgesia, in combination with the standard analgesic protocol used in the department, for conscious adult…
- Trial name
- Pen ASAP (NCT03798899)
- Testing
- Methoxyflurane, Normal Saline
- Where
- 8 sites in France
- Volunteers
- 360 people
- Sponsor
- Mundipharma SAS
Dental Pain
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery
The present study is aimed at demonstrating the therapeutic equivalence of diclofenac HPBCD 75mg/1ml s.c. with the marketed reference product, Voltarol® 75mg/3ml i.m.
- Trial name
- NCT00943098
- Testing
- Diclofenac HPBCD s.c. 75mg/ml, Voltarol 75mg/3ml i.m.
- Where
- 3 sites in United Kingdom
- Volunteers
- 142 people
- Sponsor
- IBSA Institut Biochimique SA
Acute Pain
Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe Pain
This study evaluates the safety and efficacy of DNN.63.18.040 compared with Tramal® for the treatment of moderate to severe pain.
- Trial name
- PIERRE (NCT07880392)
- Testing
- Product DNN.63.18.040, Tramal®
- Volunteers
- 370 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Acute Pain, Postoperative
Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain
The purpose of this study is to compare intravenous (IV) and oral acetaminophen for the treatment of acute moderate to severe pain in combination with standard patient-controlled analgesia (PCA) in adult subjects following total…
- Trial name
- NCT02746263
- Testing
- IV acetaminophen, Oral acetaminophen, Morphine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Mallinckrodt
Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
- Trial name
- RESTORE (NCT06987643)
- Testing
- Neflamapimod
- Where
- 10 sites in Australia
- Volunteers
- 45 people
- Sponsor
- EIP Pharma Inc
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- SPRINTER (NCT04732949)
- Testing
- SNG001
- Where
- 112 sites in United States, Argentina and 15 more
- Volunteers
- 623 people
- Sponsor
- Synairgen Research Ltd.
ARDS (Moderate or Severe), AHRF
STimulation to Activate RespIration
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute…
- Conditions
- ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients
- Trial name
- STARI (NCT06832306)
- Testing
- Phrenic Nerve Stimulation
- Where
- 7 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Lungpacer Medical Inc.
Mild to Moderate COVID-19
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19).
- Trial name
- NCT05675072
- Testing
- FB2001
- Where
- China
- Volunteers
- 1,336 people
- Sponsor
- Frontier Biotechnologies Inc.
Dehydration, Gastroenteritis
Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis
The primary objective of this study is to compare the efficacy and safety of the use of a multiple electrolyte solution to the use of saline for the treatment of moderate to severe dehydration due to acute gastroenteritis (AGE)…
- Trial name
- NCT01234883
- Testing
- multiple electrolyte solution, saline
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Baxter Healthcare Corporation
Arthritis, Gouty
Celebrex In Acute Gouty Arthritis Study
This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation…
- Trial name
- NCT00549549
- Testing
- Indomethacin, Celecoxib
- Where
- 81 sites in United States, Canada and 10 more
- Volunteers
- 402 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine Disorders, Migraine, Acute
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications…
- Trial name
- NCT00573170
- Testing
- TREXIMET®, Butalbital-containing Combination Medications (BCM)
- Where
- 107 sites in United States
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Generalized Pustular Psoriasis (GPP)
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute…
- Trial name
- NCT06231381
- Testing
- HB0034
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Postoperative Pain
Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients
This is a randomized, double-blind, multicenter, fixed dose factorial study of Q8003 12 mg/8 mg and Q8003 6 mg/4 mg versus its individual morphine sulfate and oxycodone hydrochloride components for the management of acute…
- Trial name
- NCT00831051
- Testing
- Q8003, Morphine sulfate, Oxycodone HCl
- Where
- 6 sites in United States
- Volunteers
- 197 people
- Sponsor
- QRxPharma Inc.
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations
The REVIVE Pivotal Study
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations, COPD Patients, COPD Acute Exacerbation
- Trial name
- REVIVE (NCT07361653)
- Testing
- Ryme TLD
- Volunteers
- 300 people
- Sponsor
- Ryme Medical, Inc.